Shorted
Mayne Pharma Group logo
MYX
Pharmaceuticals, Biotechnology & Life Sciences

Mayne Pharma Group

Short interest
2.28%
+0.04 pp 30d
as of 12 Oct 2026
Reported shorts
1.9M
Shares on issue
81.891M

Mayne Pharma Group (MYX) News

Latest articles and price-sensitive announcements with AI sentiment classification.

Kalkine
Positive
2d ago

Has Mayne Pharma (ASX:MYX) Secured Its Imvexxy Revenue Into the Next Decade?

Highlights Mayne Pharma has settled the last US patent challenge to its Imvexxy menopause treatment with Teva. Teva can launch a generic version early next decade, or earlier in certain circumstances, subject to court approval. Imvexxy net sales grew solidly over the last financial year. Mayne Pharma (ASX:MYX), the Adelaide-based specialty pharmaceutical company focused on women's health and dermatology in the US, has removed a key source of uncertainty for one of its important products. A se...

Continue reading
Kalkine
Neutral
14 Aug

Mayne Pharma Group Announces Director Jacob Haft Ma-Weaver’s Initial Securities Interest

Mayne Pharma Group Limited (ASX:MYX) has submitted an Initial Director's Interest Notice revealing the securities holdings of newly appointed director Jacob Haft Ma-Weaver, who joined the board on 14 August 2026. Key Points Jacob Haft Ma-Weaver was appointed to the board of Mayne Pharma Group Limited on 14 August 2026. Ma-Weaver holds no securities as a registered holder in his personal name. Funicular Funds, LP holds a relevant interest in 8,045,349 ordinary shares through TD Securities (USA...

Continue reading
Kalkine
Neutral
5 Aug

Mayne Pharma Group Announces Expiry of 24,860 Performance Rights Effective July 30, 2026

Mayne Pharma Group Limited (ASX:MYX) has informed the ASX about the expiration of 24,860 performance rights (security code: MYXAN) as of 30 July 2026, due to the failure to meet, or the impossibility of meeting, the stipulated conditions for these conditional rights. Key Highlights 24,860 MYXAN performance rights expired on 30 July 2026 as conditions were unmet or became unfulfillable No payment or consideration was made by Mayne Pharma for the termination of these securities The lapse occurr...

Continue reading
Kalkine
Neutral
5 Aug

Mayne Pharma Group Issues 161,465 Shares After Performance Rights Conversion

Mayne Pharma Group Limited (ASX:MYX) announced the issuance of 161,465 fully paid ordinary shares following the conversion of unquoted performance rights (MYXAN) on 30 July 2026. Of these, 151,439 shares were allocated to CEO Aaron Gray as part of an employee incentive scheme. Key Points 161,465 fully paid ordinary shares issued on 30 July 2026 after performance rights conversion CEO Aaron Gray received 151,439 shares as restricted stock units tied to his sign-on bonus Shares issued under a l...

Continue reading
Kalkine
Neutral
5 Aug

Mayne Pharma Names Jacob Ma-Weaver as Non-Executive Director Starting 14 August 2026

Mayne Pharma Group Limited (ASX:MYX) revealed that Jacob Ma-Weaver will join its Board as a Non-Executive Director, effective 14 August 2026, as per the company’s announcement dated 5 August 2026. Key Highlights Jacob Ma-Weaver appointed Non-Executive Director at Mayne Pharma, effective 14 August 2026 Ma-Weaver is the Managing Member and founder of Cable Car Capital, LP, established in 2013 Funicular Funds, LP, a hedge fund where Cable Car is General Partner, owns 9.90% of Mayne Pharma’s ...

Continue reading
Kalkine
Neutral
29 June

Adveritas (ASX:AV1), Mayne Pharma (ASX:MYX): Penny Stocks to Watch

Highlights Adveritas, Mayne Pharma and Wagners Holding continue attracting attention across the small-cap segment. Strong balance sheets and improving operational performance remain key themes among emerging companies. Investors continue assessing financial strength alongside long-term growth prospects within smaller ASX-listed businesses. Smaller listed companies continue drawing market attention as investors search for businesses with improving financial str...

Continue reading